GT Biopharma, Inc. (NASDAQ: GTBP) will combine every 25 issued and outstanding Common Stock shares into one share under a 1-for-25 reverse stock split.
Shareholder Votes Approve Redomestication Measures
Wellchange Holdings Co Ltd (NASDAQ: WCT) will combine every five Class A ordinary shares into one, reducing the outstanding Class A total from 52,905,328 to approximately 10,581,066. The reverse stock split takes effect whenNasdaqopens on September 8, with the shares continuing to trade under …
Magnus Vaaler, Chief Financial Officer of Borr Drilling Ltd, filed a Form 4 on September 4, 2026, disclosing a sale of common shares on September 3, 2026, effected solely to satisfy tax withholding obligations from vesting restricted stock units.
A statement of changes in beneficial ownership filed on September 4, 2026 reports that Lori Ann Flees, President and Chief Executive Officer of Valvoline Inc., acquired 30 deferred stock units on September 3, 2026 through salary deferral under the company's deferred compensation plan.
Jehan Mawjee, Chief Accounting Officer of Borr Drilling Ltd, filed a Form 4 on September 4, 2026, disclosing a sale of common shares on September 3, 2026, executed solely to satisfy tax withholding obligations arising from the vesting of restricted stock units.
Harvey Edward Snowling, Chief Operating Officer of Borr Drilling Ltd (NYSE:BORR), filed a Form 4 on September 4, 2026, reporting a sale of common shares on September 3, 2026, to satisfy tax withholding obligations from vesting restricted stock units.
Director Chen Xiaohong filed a Form 4 with the SEC on September 4, 2026, reporting changes in beneficial ownership of American Depositary Shares and Restricted Share Units in KE Holdings Inc. (NYSE:BEKE) stemming from transactions on September 2 and 3, 2026.
A Form 4 filed on September 4, 2026 discloses that Zhu Hansong, a director of KE Holdings Inc. (NYSE:BEKE), acquired American Depositary Shares through the vesting of Restricted Share Units and received a new RSU grant on September 2, 2026.
A Form 4 filed on September 4, 2026, with the SEC discloses that Peter C. Farrell, a director and chairman emeritus of ResMed Inc, sold 970 shares of ResMed common stock on September 2, 2026, under a pre-established Rule 10b5-1 trading plan.